Clinical Research Directory
Browse clinical research sites, groups, and studies.
Body Composition and Adipose Tissue in HIV
Sponsor: Columbia University
Summary
In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity. This study is a single arm prospective study of tesamorelin therapy of patients with HIV lipodystrophy. Subjects will do body composition testing, adipose tissue biopsy, metabolic rate measurements and insulin sensitivity assessment before, 6 and 12 months after daily injections of tesamorelin 2 mg by subcutaneous injection.
Official title: Body Composition and Adipose Tissue in HIV Lipodystrophy: Effects of Tesamorelin Therapy
Key Details
Gender
All
Age Range
18 Years - 68 Years
Study Type
INTERVENTIONAL
Enrollment
6
Start Date
2018-02-07
Completion Date
2025-04-30
Last Updated
2026-05-19
Healthy Volunteers
No
Interventions
Tesamorelin
Patients will be treated with tesamorelin 2 mg by subcutaneous injection daily
Locations (1)
Neuroendocrine Unit and Pituitary Center, Columbia University
New York, New York, United States